Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital-anesthetized Dogs
暂无分享,去创建一个
G. Gintant | A. King | K. Marsh | S. Mittelstadt | B. Cox | J. Polakowski | L. Preusser | R. Nelson | A. Kempf-Grote | T. J. Campbell
[1] Robert A Hegele,et al. The end of the road for CETP inhibitors after torcetrapib? , 2009, Current opinion in cardiology.
[2] P. Yildiz. Molecular mechanisms of pulmonary hypertension. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[3] R. Obach,et al. Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans , 2008, Drug Metabolism and Disposition.
[4] C. Prakash,et al. Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance , 2008, Drug Metabolism and Disposition.
[5] Jean-Pierre Valentin,et al. Safety and secondary pharmacology: successes, threats, challenges and opportunities. , 2008, Journal of pharmacological and toxicological methods.
[6] P. Baldrick. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies. , 2008, Regulatory toxicology and pharmacology : RTP.
[7] J. Ehrhart,et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone , 2008, British journal of pharmacology.
[8] S. Doggrell. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? , 2008, Expert opinion on pharmacotherapy.
[9] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[10] Jean-Claude Tardif,et al. Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.
[11] A. Tall,et al. The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[12] J. Mckenney,et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.
[13] D. Rader,et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.
[14] T. Sand,et al. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[15] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[16] R H Fagard,et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. , 1999, Archives of internal medicine.
[17] J D Thomas,et al. Noninvasive assessment of the ventricular relaxation time constant (tau) in humans by Doppler echocardiography. , 1997, Circulation.
[18] G. Assmann,et al. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. , 1992, The American journal of cardiology.
[19] R S Reneman,et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.
[20] R. Fryer,et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. , 2008, American journal of physiology. Heart and circulatory physiology.
[21] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.